Table 2.
Comparison of the tumour and liver uptake of radioimmunoconjugates (RICs) estimated by region of interest (ROI) analysis of PET images and biodistribution (BOD) studies
| Percent injected dose/g (mean ± SEM) | ||||||
|---|---|---|---|---|---|---|
| Tumour | Liver | |||||
| Time p.i. | PETa | BODb | P-valuec | PETa | BODb | P-valuec |
| 6 h | 8.8 ± 2.3 | 9.3 ± 1.0 | n.s. | 11.2 ± 0.5 | 8.4 ± 0.8 | n.s. |
| 24 h | 10.3 ± 1.3 | 14.9 ± 1.1 | n.s. | 9.5 ± 0.2 | 7.5 ± 1.0 | n.s. |
| 48 h | 10.9 ± 1.1 | 9.8 ± 1.3 | n.s. | 7.2 ± 0.3 | 6.2 ± 0.1 | 0.04 |
aUptake of [64Cu]Cu-DOTA-panitumumab Fab´)2 estimated by ROI analysis of PET images expressed in percent injected dose/g (%ID/g; mean ± SEM, n = 4)
bUptake of [64Cu]Cu-DOTA-panitumumab F(ab´)2 estimated by BOD analysis expressed in %ID/g (mean ± SEM, n = 4)
cComparison of ROI and BOD analysis by a Mann-Whitney U test (P < 0.05)